This volume is comprised of papers presented at the Third International Conference on Pharmacoepidemiology, held September 9-11, 1987, in Minneapolis, Minnesota. The book is divided into four sections, which reflect the four themes of the conference: Social Impact of Pharmacoepidemiology; Drug Epidemiology and the Law; Drug Surveillance; and Drugs, Populations, and Outcomes: Specific Studies. The collection of papers discusses the social and legal impact of epidemiology, the system of checks and balances that is necessary for the field, the importance of core support for researchers, and the goal of an enlightened and informed public, including the media, consumer advocates, and the courts. Contributing authors offer perspectives from academia, practice, government, industry and the law. Numerous tables and figures are included to illustrate many of the papers within the text. This book offers substantial reading for epidemiologists and individuals interested in the field of pharmacoepidemiology.
Table of Contents
SECTION ONE: SOCIAL IMPACT OF PHARMACOEPIDEMIOLOGY. Introduction. Pharmacoepidemiology and Public Policy. Risk Assessment of New Drugs, Pharmacoepidemiology, and Regulatory Decisionmaking. Industry Perspectives and the Contributions of Pharmacoepidemiology to Public Health. SECTION TWO: DRUG EPIDEMIOLOGY AND THE LAW. Introduction. Impact of Drug Products Liability on Needs for Pharmacoepidemiologic Studies and Expertise. Epidemiology in the Courtroom: Anatomy of an Intellectual Embarrassment. SECTION THREE: DRUG SURVEILLANCE. Introduction. A Brief Review of the Yellow Card Adverse Reaction Reporting Scheme in the United Kingdom. Frequency Analysis of Spontaneous Reports from Different Countries: The Example of Continental Western Europe. Evaluation of First Year Experience of a State Pilot Project to Promote Physician Reporting of Adverse Drug Events to the Food and Drug Administration. Monitoring System for Adverse Events Following Immunization Risk Factors for Convulsions After Vaccination. Application of a New Method for Adverse Experience Monitoring to Premarketing Studies on Two New Drugs: Some Experiences. A Nationwide Drug Surveillance Network. The Pharmacoepidemiology Data Base of the Brigham and Women's Hospital. Overcoming Limitations of Routine Surveillance of Drug Overdose. Current Status of the Saskatchewan Prescription Drug Plan. Early Experience with the COMPASS Data Base. Postmarketing Surveillance in Tayside: A Further Assessment of Record Linkage Using Five Nonsteroidal Anti-inflammatory Drugs. SECTION FOUR: DRUGS, POPULATIONS, AND OUTCOMES: SPECIFIC STUDIES. Introduction. Nonsteroidal Anti-inflammatory Drugs and Upper Gastrointestinal Bleeding. Impact of Nonsteroidal Anti-inflammatory Agents on General Gastrointestinal Upset in an Elderly Population. NSAIDs as a Cause of Morbidity from Peptic Ulcer Complications in New South Wales. The Relationship Between Rheumatoid Arthritis and Risk of Cancer, Controlling for the Effect of Drugs, in Hospitalized Patients of Saskatchewan, Canada. Collaborative Study of the Effects of Acyclovir in Pregnancy. Creutzfeldt-Jakob Disease, Human Growth Hormone, and its Replacement with Synthetic Growth Hormone. Retrovir: The Challenge of Postmarketing Surveillance. Differences in Psychotropic Medications Reported Used by Blacks and Whites.The Dunedin Program: A Longitudinal Study of Aging. Psychotropic Drug Use and Health Outcomes in Nursing Homes. What is the Cost of Nephrotoxicity Associated with Aminoglycosides? Appendix. INDEX